These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 24638006)
1. Survival benefit from response-guided approach: a direct effect of more effective cytotoxic regimens or an indirect effect of chemotherapy-induced amenorrhea? Reply to K.-D. Yu et al. von Minckwitz G; Loibl S J Clin Oncol; 2014 Apr; 32(12):1283-4. PubMed ID: 24638006 [No Abstract] [Full Text] [Related]
2. Survival benefit from response-guided approach: a direct effect of more effective cytotoxic regimens or an indirect effect of chemotherapy-induced amenorrhea? Yu KD; Shao ZM J Clin Oncol; 2014 Apr; 32(12):1282-3. PubMed ID: 24638014 [No Abstract] [Full Text] [Related]
3. Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer. Telli ML J Clin Oncol; 2013 Oct; 31(29):3613-5. PubMed ID: 24002503 [No Abstract] [Full Text] [Related]
4. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. Walshe JM; Denduluri N; Swain SM J Clin Oncol; 2006 Dec; 24(36):5769-79. PubMed ID: 17130515 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB. Kim R; Osaki A; Tanabe K; Toge T Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565 [TBL] [Abstract][Full Text] [Related]
6. Response-guided neoadjuvant chemotherapy for breast cancer. von Minckwitz G; Blohmer JU; Costa SD; Denkert C; Eidtmann H; Eiermann W; Gerber B; Hanusch C; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Kümmel S; Paepke S; Schneeweiss A; Untch M; Zahm DM; Mehta K; Loibl S J Clin Oncol; 2013 Oct; 31(29):3623-30. PubMed ID: 24002511 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy for operable breast cancer: individualizing locoregional and systemic therapy. Bear HD Surg Oncol Clin N Am; 2010 Jul; 19(3):607-26. PubMed ID: 20620930 [TBL] [Abstract][Full Text] [Related]
8. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer]. Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634 [TBL] [Abstract][Full Text] [Related]
9. Analysis of neoadjuvant therapies in breast cancer with respect to pathological complete response, disease-free survival and overall survival: 15 years follow-up data from Kuwait. Krishnan Y; Al Awadi S; Sreedharan PS; Sujith Nair S; Thuruthel S Asia Pac J Clin Oncol; 2016 Mar; 12(1):e30-7. PubMed ID: 23937427 [TBL] [Abstract][Full Text] [Related]
10. [Certain aspects of neoadjuvant therapy of locally advanced breast cancer]. Voznyĭ EK; Gurov SN; Dobrovol'skaia NIu Vopr Onkol; 2001; 47(6):690-4. PubMed ID: 11826490 [TBL] [Abstract][Full Text] [Related]
11. Ovarian suppression for prevention of premature menopause and infertility: empty promise or effective therapy? Partridge AH J Clin Oncol; 2012 Feb; 30(5):479-81. PubMed ID: 22231046 [No Abstract] [Full Text] [Related]
12. Neoadjuvant chemotherapy for breast cancer: any progress? Colleoni M; Goldhirsch A Lancet Oncol; 2014 Feb; 15(2):131-2. PubMed ID: 24360786 [No Abstract] [Full Text] [Related]
13. Neoadjuvant chemotherapy in the treatment of breast cancer. Redden MH; Fuhrman GM Surg Clin North Am; 2013 Apr; 93(2):493-9. PubMed ID: 23464698 [TBL] [Abstract][Full Text] [Related]
14. [Neoadjuvant Chemotherapy in breast cancer]. Suzuki E; Toi M Nihon Rinsho; 2006 Mar; 64(3):536-9. PubMed ID: 16529046 [TBL] [Abstract][Full Text] [Related]
15. [Neoadjuvant chemotherapy of patients with breast carcinoma]. Jakesz R; Taucher S; Gnant M; Gebhard B; Kandioler D; Rudas M; Djavanmard M; Steger G Zentralbl Chir; 1998; 123 Suppl 5():147-50. PubMed ID: 10063601 [TBL] [Abstract][Full Text] [Related]
16. [Response and prognosis of neoadjuvant dose-dense or standard schedule chemotherapy with anthracyclines and taxanes for Luminal B breast cancer]. Qiu AF; Miao ZL; Ge GK; Wang CB; Bian J; Ma HY; Xu Q Zhonghua Yi Xue Za Zhi; 2017 Nov; 97(44):3466-3470. PubMed ID: 29275580 [No Abstract] [Full Text] [Related]
17. Node micrometastases detection after neoadjuvant chemotherapy in breast cancer: is it of clinical value? Ziogas D; Harissis H; Batsis C Ann Surg Oncol; 2010 Mar; 17(3):933-4; author reply 935. PubMed ID: 19830493 [No Abstract] [Full Text] [Related]
18. Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR. Generali D; Corona SP; Pusztai L; Rouzier R; Allevi G; Aguggini S; Milani M; Strina C; Frati A J Cancer Res Clin Oncol; 2018 Mar; 144(3):601-606. PubMed ID: 29344722 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy for operable breast cancer. Green M; Hortobagyi GN Oncology (Williston Park); 2002 Jul; 16(7):871-84, 889; discussion 889-90, 892-4, 897-8. PubMed ID: 12164555 [TBL] [Abstract][Full Text] [Related]
20. Reply to "Anti-cytokeratin CAM5.2 recognized CK8 mainly, but not CK18: comment on 'Early assessment of axillary response with 18F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol. 2013;20(7):2227-35'". Koolen BB; Wesseling J Ann Surg Oncol; 2014 Feb; 21(2):700. PubMed ID: 24052316 [No Abstract] [Full Text] [Related] [Next] [New Search]